These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 22016474)

  • 1. The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists.
    Joh JE; Esposito NN; Kiluk JV; Laronga C; Lee MC; Loftus L; Soliman H; Boughey JC; Reynolds C; Lawton TJ; Acs PI; Gordan L; Acs G
    Oncologist; 2011; 16(11):1520-6. PubMed ID: 22016474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer.
    Lee SH; Ha S; An HJ; Lee JS; Han W; Im SA; Ryu HS; Kim WH; Chang JM; Cho N; Moon WK; Cheon GJ
    Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1574-84. PubMed ID: 27209424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?
    Asad J; Jacobson AF; Estabrook A; Smith SR; Boolbol SK; Feldman SM; Osborne MP; Boachie-Adjei K; Twardzik W; Tartter PI
    Am J Surg; 2008 Oct; 196(4):527-9. PubMed ID: 18809056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implications of the 21-gene recurrence score assay (Oncotype DX) on adjuvant treatment decisions in ER-positive early-stage breast cancer patients: experience of Kuwait Cancer Control Center.
    Fayaz S; Eissa HE; Demian GA
    J Egypt Natl Canc Inst; 2020 Mar; 32(1):13. PubMed ID: 32372329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Agreement in risk prediction between the 21-gene recurrence score assay (Oncotype DX®) and the PAM50 breast cancer intrinsic Classifier™ in early-stage estrogen receptor-positive breast cancer.
    Kelly CM; Bernard PS; Krishnamurthy S; Wang B; Ebbert MT; Bastien RR; Boucher KM; Young E; Iwamoto T; Pusztai L
    Oncologist; 2012; 17(4):492-8. PubMed ID: 22418568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer.
    Dodson A; Okonji D; Assersohn L; Rigg A; Sheri A; Turner N; Smith I; Parton M; Dowsett M
    Breast Cancer Res Treat; 2018 Feb; 168(1):249-258. PubMed ID: 29128896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of 21-gene recurrence score assay for hormone receptor-positive, lymph node-negative breast cancer in early stage.
    Yu-Qing Y; Lei W; Mei-Ling H; Jing-Jing X; Mei-Chen W; Jiang W; Jun-Sheng H; Rui L; Nan-Lin L
    Exp Mol Pathol; 2019 Jun; 108():150-155. PubMed ID: 31026440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlating Ki67 and other prognostic markers with Oncotype DX recurrence score in early estrogen receptor-positive breast cancer.
    Tan AC; Li BT; Nahar K; Danieletto S; Fong ES; Currer T; Parasyn A; Middleton P; Wong H; Smart D; Rutovitz JJ; McCloud P; Hughes TM; Marx GM
    Asia Pac J Clin Oncol; 2018 Apr; 14(2):e161-e166. PubMed ID: 28960862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer.
    Partin JF; Mamounas EP
    Ann Surg Oncol; 2011 Nov; 18(12):3399-406. PubMed ID: 21537874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can features evaluated in the routine pathologic assessment of lymph node-negative estrogen receptor-positive stage I or II invasive breast cancer be used to predict the Oncotype DX recurrence score?
    Auerbach J; Kim M; Fineberg S
    Arch Pathol Lab Med; 2010 Nov; 134(11):1697-701. PubMed ID: 21043825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Prognostic Significance of the Oncotype DX Recurrence Score in T
    Wang M; Wu K; Zhang P; Zhang M; Ding A; Chen H
    Ann Surg Oncol; 2019 May; 26(5):1227-1235. PubMed ID: 30456680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secondary Invasive Breast Events among Patients with Hormone-Positive Breast Cancer and High-Risk Oncotype DX Recurrence Scores 26-30 and ≥31.
    Berger NF; Zimmerman BS; Tharakan S; Suchman K; Cascetta KP; Blanter J; Moshier E; Ru M; Jaffer S; Tiersten A
    Oncology; 2021; 99(11):699-702. PubMed ID: 34425579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Oncotype DX Recurrence Score as a prognostic factor in Japanese women with estrogen receptor-positive, node-negative primary Stage I or IIA breast cancer.
    Yorozuya K; Takeuchi T; Yoshida M; Mouri Y; Kousaka J; Fujii K; Nakano S; Fukutomi T; Hara K; Ichihara S; Lin Y; Kikuchi S
    J Cancer Res Clin Oncol; 2010 Jun; 136(6):939-44. PubMed ID: 19946706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating use characteristics for the oncotype dx 21-gene recurrence score and concordance with chemotherapy use in early-stage breast cancer.
    Chen C; Dhanda R; Tseng WY; Forsyth M; Patt DA
    J Oncol Pract; 2013 Jul; 9(4):182-7. PubMed ID: 23942918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of Oncotype DX score in clinical management for T1 estrogen receptor positive, HER2 negative, and lymph node negative breast cancer.
    Nguyen TTA; Postlewait LM; Zhang C; Meisel JL; O'Regan R; Badve S; Kalinsky K; Li X
    Breast Cancer Res Treat; 2022 Apr; 192(3):509-516. PubMed ID: 35084624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial).
    Penault-Llorca F; Filleron T; Asselain B; Baehner FL; Fumoleau P; Lacroix-Triki M; Anderson JM; Yoshizawa C; Cherbavaz DB; Shak S; Roca L; Sagan C; Lemonnier J; Martin AL; Roché H
    BMC Cancer; 2018 May; 18(1):526. PubMed ID: 29728098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: American Society of Clinical Oncology Endorsement of Cancer Care Ontario Guideline Recommendations.
    Henry NL; Somerfield MR; Abramson VG; Allison KH; Anders CK; Chingos DT; Hurria A; Openshaw TH; Krop IE
    J Clin Oncol; 2016 Jul; 34(19):2303-11. PubMed ID: 27001586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of Oncotype Dx recurrence score using clinical parameters: A comparison of available tools and a simple predictor based on grade and progesterone receptor.
    Thibodeau S; Voutsadakis IA
    Hematol Oncol Stem Cell Ther; 2019 Jun; 12(2):89-96. PubMed ID: 30796885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship of histologic grade and histologic subtype with oncotype Dx recurrence score; retrospective review of 863 breast cancer oncotype Dx results.
    Singh K; He X; Kalife ET; Ehdaivand S; Wang Y; Sung CJ
    Breast Cancer Res Treat; 2018 Feb; 168(1):29-34. PubMed ID: 29230662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.